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Genistein, a soy isoflavone with anti-tumor properties, has both estrogenic and non-estrogenic activities. Genistein sensitive/estrogen receptor
negative (ER-) MDA-MB-231 cells and genistein resistant/ER+MCF-7 cells are frequently cited as examples of differential responses to genistein
due to different ER status. Other factors that may affect genistein response, however, are largely unknown. Based on our finding that MCF-7 is
caspase-3 deficient, we examined whether caspase-3 status plays a role in the differential responses between the two cell lines. We demonstrate
that reconstitution of caspase-3 significantly sensitizes MCF-7 cells to genistein. Specific knockdown of caspase-3 in MDA-MB-231 cells renders
the cells resistant to genistein. We also found that caspases-4 and -10 were downregulated in MCF-7 cells. Reconstitution of caspase-10 in MCF-7
cells, however, resulted in little sensitization. Moreover, we show that caspase-3 downregulation is very common in breast cancer cell lines and
tumor tissues. Taken together, our data indicate that caspase-3 is a critical determinant of cellular response to genistein, which may have important
implications in studying soy/genistein-mediated anti-tumor activities.
© 2007 Elsevier B.V. All rights reserved.Keywords: Genistein; Caspase-3; Apoptosis; Breast cancer; MCF-7; MDA-MB-2311. Introduction
A low incidence of breast cancer in Asian women has been
associated with a diet high in soy products [1], and many soy-
mediated anti-tumor properties have been attributed to
genistein, a major soy isoflavone [2]. Identification of the
factors that affect genistein-mediated tumor inhibition is of
great significance in the implication of soy/genistein in tumor
prevention and/or treatment. Available evidence suggests
genistein functions by modulating multiple signaling path-
ways [3], including estrogen receptor (ER) pathway [4],
receptor tyrosine kinase (RTK) pathways [5], and NF-KB
pathway [6]. Phenotypically, genistein-induced apoptosis and/
or cell cycle arrest links the modified cellular activities and
tumor growth inhibition [3].
The response of breast cancer cells to genistein vary
significantly from cell line to cell line [3,7–9]. In vitro and in
vivo results indicate genistein dose and estrogen dependency⁎ Corresponding author. Tel.: +1 405 271 1524; fax: +1 405 271 2568.
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doi:10.1016/j.bbamcr.2007.03.021of the cancer cells appear to be the most prominent factors
[10] associated with genistein's SERM (selective estrogen
receptor modulator) property [11]. For ER-α negative/
estrogen-independent cells, such as MDA-MB-231 cells,
genistein inhibits cell growth at both low and high con-
centrations [12,13]. Nevertheless, genistein exhibits a con-
centration dependent bi-phasic effect on ER-α positive/
estrogen-dependent cells, such as MCF-7. In these cells,
genistein promotes cell growth at a lower concentration
(b5 μM), while inhibiting growth at a higher concentration
(N10 μM) [14–17]. Among the numerous cell lines tested,
MCF-7 and MDA-MB-231 cell lines are the most popular
breast cancer cell lines used for genistein studies [12,13,17–
19]. Most studies indicate that MDA-MB-231 cells are more
sensitive than MCF-7 [4,9,20–22], although one group
reported that MCF-7 cells were more sensitive than MDA-
MB-231 cells [23]. Currently, the differential responses to
genistein between the two cell lines are primarily explained
by their ER status [4,18,24–26]. While ER status is critical in
genistein responses, the two cell lines are also distinctive in
p53 and caspase-3 status, both of which are critical in cell cycle
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mutant p53 and functional caspase-3 [12,23], whereas MCF-7
cells express wild type p53 and are caspase-3 deficient
[23,27,28].
Caspase-3 is a key member of the caspase family, a group
of cysteine proteases that mediate apoptotic execution [29]. It
can be activated by apoptotic signals from both death receptor
and intracellular/mitochondrial pathways [30]. Caspase-3
functions as a major effector caspase by cleavage of
numerous cell death substrates, to cellular dysfunction and
destruction [31]. Involvement of caspase-3 in genistein-
induced apoptosis has been detected in previous studies
[11,12,32]. Given the functional overlap among the caspase
family members and the different status of p53 between
MCF-7 and MDA-MB-231 cells lines, however, it is unclear
if and how much caspase-3 status contributes to the
differential response to genistein. Recently, caspase-3 defi-
ciency and downregulation have been associated with breast
carcinogenesis [33], suggesting caspase-3 could be a bio-
marker in cancer prevention and treatment. This is supported
by our previous reports showing that functional caspase-3 is
critical for effective chemo- and radio-therapy [34,35]. In this
report, we studied the role of caspase-3 in genistein-induced
apoptosis by characterization of apoptosis in caspase-3
reconstituted MCF-7 cells and MDA-MB-231 cells with
caspase-3 knockdown. We found that caspase-3 status, in
addition to ER status, significantly contributes to the dif-
ferential responses between the two cell lines. While our data
clarifies an important issue in genistein responses in breast
cancer cell lines, it also underscores the significance of
apoptosis, and caspase-3 in particular, in genistein-mediated
anti-tumor mechanisms.
2. Materials and methods
2.1. Reagents
DMEM/F12 medium, genistein, 5-diphenyltetrazolium bromide (MTT),
and other chemicals were purchased from Sigma (St. Louis, MO). Antibodies
against caspases-3, -4 and -10, and Actin were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Antibody against ER-α was from Upstate
Biotechnology, Inc. (NY). Antibody against Poly (ADP-ribose) polymerase
(PARP) was from BD Biosciences (San Diego, CA). Horseradish peroxidase
(HRP)-labeled secondary antibodies were purchased from Amersham/GE
Health Care (Arlington Height, IL). Caspase multiplex PCR set-5 and 6 were
purchased from BioSources (Carmarillo, CA). Apoptosis ELISA kit was from
Roche Diagnostics (Indianapolis, IN).
2.2. Cell lines, cell culture and breast tumor tissues
MCF-7 and MDA-MB-231 cells, and all the other cells lines tested in Fig.
4 were from ATCC. MCF-7/PV and MCF-7/C3 cells are stable MCF-7 cell
lines transfected with pBabe/puro vector or caspase-3 encoding vector as
described before [35]. MCF-7/C10 cell line was established by transfecting
MCF-7 cells with caspase-10 (Mch4) encoding plasmid followed by G418
selection [27]. The cells were cultured in DMEM/F12 medium containing
10% fetal bovine serum (FBS). To prepare for protein lysate, the cells were
inoculated into 60 mm dish at 1×106/ dish 24 h before genistein treatment
and sample collection. The controls for genistein treatment were the cells
treated with 0.1% DMSO (solvent for genistein) at the indicated time.
Primary breast tumor samples were obtained from patients who hadundergone breast surgery at Evanston Northwestern Healthcare Research
Institute with Institutional Review Board (IRB) approval.
2.3. MTT assay
The cells were inoculated into 96-well-plate at 1×103 cells/well, or 24-well-
plate at 3×103 cells/well 24 h before the treatment. The cells were then treated
with increasing concentrations of genistein at indicated concentrations for
6 days. After removal of the medium, 50 μl of MTT solution (500 μg/ml) was
added to each well followed by 4 h incubation. MTT solution was replaced by
DMSO to dissolve blue formazan crystals, and absorbance was measured at
562 nm using a microplate reader. Each group contains 8 parallel samples.
Survival fractions were calculated as the absorbance in the treated cells over the
control (treated with 0.1% DMSO). Statistical differences were analyzed with
Student's t-test.
2.4. Western blot
Control and drug treated cells or primary breast cancer tissues were lysed
with lysis buffer [36] on ice for 30 min. Protein concentration was determined
using BCA assay kit (Pierce Biotechnology Inc. IL). Fifty μg of protein lysate
was loaded onto each lane of a gel. Proteins were separated with 12% SDS-
PAGE and transferred to nitrocellulose membrane. The membrane was probed
with a specific primary antibody at a dilution of 1:1000 to 2000, followed by
washing and probing with a corresponding secondary antibody. The specific
protein band was visualized by autoradiography using an ECL kit.
2.5. Short hairpin RNA (shRNA) transfection
For silencing the expression of caspase-3 in MDA-MB-231 cells, caspase-
3 specific and control shRNA (New England Biolab, Ipswich, MA) was
transfected into the cells using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer's protocol. For the preparation of Western
blot lysate, 3×105 cells were inoculated into each well of 6-well plates 24 h
before transfection. The cells in each well were transfected with 200 pmol of
control or caspase-3 specific shRNA. Genistein was added 16 h after
transfection. Cell lysates were collected 48 h post transfection. For MTT
assay, the cells were inoculated into 24-well plate at 3000 cells/well. shRNA
was transfected as above. Genistein at indicated concentrations were added to
the transfected cells 16 h post transfection and left for 4 days before MTT
assay.
2.6. RNA extraction, reverse transcription (RT), and multiplex PCR
Total RNA of indicated cell lines was isolated using RNeasy Mini Kit
(QIAGEN, CA). First strand cDNA synthesis was performed using Super-
scriptIII™ First Strand synthesis system (Invitrogen). After reverse transcription
(RT) with 3 μg of total RNA, one tenth of the RT product was used as template
for PCR reaction. mRNA levels of specific caspases were detected using 2 sets
of multiplex PCR kits, which are set 5 and set 6 of the apoptosis series of
multiplex PCR from BioSource (Carmarillo, CA). With gene specific primers,
set 5 detects caspases-3, -5, -8, -9, Apaf-1, and GAPDH. Set 6 detects caspases-2,
-4, -6, -7, -10, and GAPDH. Following the manufacturer's protocol, cDNAs of
specific caspases were amplified for 30 cycles. Twenty μl of PCR products were
electrophoresed on 2% agarose gel and visualized by Ethidium Bromide
staining. The image was acquired and analyzed using UPVII gel documentation
system.
2.7. Apoptosis detection by ELISA
Induction of apoptosis was assessed with a cell death detection ELISA kit
(Roche Diagnostics) by following the manufacturer's instruction. This test is
based on the quantitative determination of cytoplasmic histone-associated DNA
fragments in the form of mononucleosomes and oligonucleosomes after induced
apoptotic death. In brief, cells in a 24-well plate were treated with genistein at
indicated concentrations for 30 h. Both floating and adherent cells were
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parallel samples, the data were analyzed using Student's t-test.
3. Results
3.1. Differential responses to genistein and the status of ER and
caspase-3 in MCF-7 and MDA-MB-231 cells
As a basis for further characterization of genistein-induced
cellular response in MDA-MB-231 and MCF-7 cells, we first
examined cell proliferation/growth inhibition of the two cell
lines post genistein using MTT assay. As shown in Fig. 1A,
MDA-MB-231 cells were more sensitive to genistein than
MCF-7 cells. Analysis of the response patterns indicates
genistein inhibits MDA-MB-231 cells in a concentration
dependent manner, whereas genistein treatment resulted in a
bi-phasic response in MCF-7 cells, which are consistent with
previous reports [37]. To demonstrate the expression of ER and
caspase-3 in MDA-MB-231 and MCF-7 cells, we then
examined the protein levels of ER-α and caspase-3 in the two
cell lines. Immunoblot analysis indicated MCF-7 cells express
high levels of ER-α and non-detectable caspase-3. In contrast,
MDA-MB-231 cells express very low levels of ER-α but highFig. 1. Different ER-α and caspase-3 status and genistein responses in MCF-7
and MDA-MB-231 cells. (A) MDA-MB-231 cells are more sensitive to
genistein than MCF-7 cells. Cells from each line were inoculated into 96-well
plates at 1000 cells/well. Genistein was added 24 h later for a 6-day treatment.
Cell survival fractions were measured using MTT assay as detailed in Materials
and methods. (B) Expression of ER-α and caspase-3 in MCF-7 and MDA-MB-
231 cells detected with Western blot.levels of caspase-3. These results suggest that besides ER-α
status, caspase-3 status may also contribute to the differential
responses between the two cell lines.
3.2. Reconstitution of caspase-3 sensitizes MCF-7 cells to
genistein
To test whether caspase-3 deficiency contributes to genistein
resistance in MCF-7 cells, we studied the effect of genistein on
MCF-7/PV and MCF-7/C3 cells, which are MCF-7 cells
transfected with control vector and caspase-3, respectively
(Fig. 2A) [35]. As shown in Fig. 2B, the survival fractions of
genistein treated MCF-7/C3 cells were consistently lower than
MCF-7/PV cells, even at lower concentrations, indicating
caspase-3 reconstitution significantly sensitizes MCF-7 cells.
We also have results suggesting the sensitization was not caused
by modified ER-α levels (data not shown). To examine the
effect of caspase-3 on genistein-induced apoptosis in MCF-7/
C3 cells, we detected the cleavage of PARP, a common
proteolytic marker of apoptosis [38], in genistein treated MCF-
7/PV and MCF-7/C3 cells (Fig. 2C). A significant increase in
PARP cleavage, as indicated by the production of p85 subunit in
genistein treated MCF-7/C3 cells, suggests caspase-3 sensitizes
MCF-7 cells to genistein by inducing enhanced apoptosis. In
MCF-7/C3 cells treated with 25 μM of genistein, we observed
increase in both total PARP and the cleaved product (p85).
Increase in total PARP is likely caused by increased PARP
expression, because we have data showing that phytoestrogens,
including genistein, induces PARP expression at higher
concentrations in MCF-7 cells (unpublished data). To further
demonstrate that caspase-3 reconstitution sensitizes MCF-7
cells to genistein through enhanced apoptosis, we evaluated
apoptotic responses in the paired cell lines using an apoptosis
ELISA kit from Roche. As shown in Fig. 2D, apoptotic readings
in genistein treated MCF-7/C3 cells were significantly higher
than those in the control cells under the same conditions. Taken
together, results from caspase-3 specific MCF-7 cell lines
demonstrate that functional caspase-3 is critical to genistein-
induced apoptosis and suggests caspase-3-deficiency in MCF-7
cells contributes to its resistance to genistein.
3.3. Caspase-3 knockdown in MDA-MB-231 cells renders the
cells more resistant to genistein
To demonstrate the specific role of caspase-3 in genistein-
mediated apoptosis in MDA-MB-231 cells, we examined the
effect of caspase-3 knockdown on genistein-mediated growth
inhibition in MDA-MB-231 cells. As shown in Fig. 3A,
transfection of caspase-3 specific shRNA resulted in sig-
nificant downregulation of caspase-3. MDA-MB-231 cells
with caspase-3 knockdown displayed reduced growth inhibi-
tion as compared to the cells transfected with control
oligonucleotides (Fig. 3B). Consistently, caspase-3 knock-
down in MDA-MB-231 cells led to decreased PARP cleavage
(Fig. 3C). Quantitative results from apoptosis ELISA assay
also showed that caspase-3 knockdown significantly inhibited
genistein-mediated apoptosis in these cells (Fig. 3D). These
Fig. 2. Caspase-3 reconstitution sensitizes MCF-7 cells to genistein. (A)
Caspase-3 status in control (MCF-7/PV) and caspase-3 reconstituted (MCF-7/
C3) MCF-7 cells detected with Western blot. (B) Genistein-mediated growth
inhibition in MCF-7/PV and MCF-7/C3 cells. Survival fractions of genistein
treated cells based on 8 parallel samples were determined using MTT assay.
*pb0.01 as compared to MCF-7/PV cells under the same conditions. (C) PARP
cleavage in genistein-treated MCF-7/PVandMCF-7/C3 cells. Each cell line was
treated with genistein at indicated concentrations for 48 h, followed by Western
blot detection of PARP. (D) Genistein-induced apoptosis in control (MCF-7/PV)
and MCF-7/C3 cells. Cells from each line were inoculated into 24 well plates at
1×105/well 24 h, followed by genistein treatment for 30 h. Apoptosis in the
treated cells was detected using an apoptosis ELSIA kit from Roche.
906 S. Yang et al. / Biochimica et Biophysica Acta 1773 (2007) 903–911results indicate that functional caspase-3 is essential in
genistein-induced apoptosis and growth inhibition in MDA-
MB231 cells and functional caspase-3 in these cells con-
tributes to their sensitive response to genistein.
3.4. Downregulation of caspase-3 in breast cancer cell lines
and tissues
Results from the above experiments suggest that caspase-3
status is associated with cellular response to genistein treatment,
and that breast cancer cells with downregulated caspase-3 might
be resistant to genistein treatment. To explore the clinical
relevance of caspase-3 status in predicting response to genistein
treatment, we examined caspase-3 protein levels in 18 breast
cancer cell lines and 9 primary breast cancer tissues (Fig. 4).
The results indicate that caspase-3 levels varied significantly
among different cell lines. As compared to the other cell lines,
HS-578T, T47D, MDA-MB-415, ZR-75-1, and SK-BR-3 cells
express lower levels of caspase-3 than the other cell lines.
Among the primary breast cancer tissues, three of nine
expressed very low levels of caspase-3. This suggests that
caspase-3 downregulation is common in breast cancers and that
breast cancers with caspase-3 downregulation may be resistant
to genistein.
3.5. Differential regulation of multiple caspases between
MCF-7/and MDA-MB-231 cells
Recent advances suggest that in addition to proteolytic
activation, caspase activity is also regulated by other mechan-
isms, such as DNA methylation and differential transcription
[39,40]. We then asked whether the expression of other caspases
is also differentially regulated between MCF-7 and MDA-MB-
231 cells. To this end, we examined the mRNA levels of
caspases-3, -4, -6, -7, -8, -9, -10, and Apaf-1 in control and
genistein treated MCF-7 and MDA-MB-231 cells using multi-
plex PCR (Fig. 5). In this experiment, the band of caspase-3 was
detected in MCF-7 cells, which might be the truncate transcript
of caspase-3 mRNA that does not yield a mature protein [28].
Analysis of other caspases indicates MDA-MB-231 cells also
express higher basal levels of caspases-4 and -10 than MCF-7
cells. This was confirmed by the protein levels of caspases-4
and -10, detected using Western blots (Fig. 5B). Furthermore,
genistein treatment also upregulated Apaf-1 and caspase-8 in
MDA-MB231 cells, suggesting that not only the basal level,
but also the dynamic regulation of certain caspases, were
also different between the two cell lines. Specific roles of
differentially regulated caspases-4, -8, -10, and Apaf-1 be-
tween the two cell lines will be followed in future studies.
3.6. Reconstitution of caspase-10 has little effect on
genistein-induced apoptosis in MCF-7 cells
In our previous studies on granzyme B-induced apoptosis
[27], we had established an MCF-7 subline that overexpresses
caspase-10 (MCF-7/C10) (Fig. 6A). To test whether reconstitu-
tion of caspase-10 sensitizes MCF-7 cells to genistein, we
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(MCF-7/PV) and MCF-7/C10 cells using MTT assay. As
shown in Fig. 6B, caspase-10 reconstitution failed to sensitize
MCF-7 to genistein to a significant level. Consistently,
genistein-induced apoptosis in both cell lines measured with
the apoptosis ELISA revealed similar results (Fig. 6C). These
data suggest that the role of caspase-10 in genistein-inducedFig. 3. Caspase-3 knockdown in MDA-MB-231 cells renders the cells resistant
to genistein. (A) Caspase-3 levels in control and caspase-3 shRNA transfected
cells. MDA-MB-231 cells were transfected with control or caspase-3 specific
shRNA as described in Materials and methods. Protein lysate were collected
48 h, followed by caspase-3 detection using Western blot. (B) Genistein-
mediated growth inhibition in control and caspase-3 shRNA transfected cells.
MDA-MB-231 cells transfected with control or caspase-3 specific shRNAwere
treated with genistein 16 h post transfection. The survival fractions of the treated
(a 4-day treatment) cells based on three parallel samples were determined by
MTT assay. *pb0.01 as compared to MDA-MB-231 cells transfected with
control siRNA under the same conditions. (C) PARP cleavage in genistein
treated MDA-MB-231 cells transfected with control or caspase-3 specific
shRNA. shRNA transfected cell were treated with genistein at indicated
concentrations for 48 h, followed by Western blot detection of PARP. (D) Effect
of caspase-3 knockdown on genistein-induced apoptosis in MDA-MB-231 cells.
The cells were inoculated in a 24-well plate at 8×104/well 16 h, followed by
transfection with control (−) or caspase-3 specific shRNA (+) and genistein
treatment at 25 μM for 30 h. Apoptosis in the treated cells was detected using an
apoptosis ELSIA kit from Roche. *pb0.01 as compared to genistein treated
MDA-MB-231 cells transfected with control siRNA.
Fig. 4. Expression of caspase-3 in 18 breast cancer cell lines and 9 primary
breast cancer tissues. Protein lysates were prepared from non-synchronized cells
of the indicated cell lines (A and B) or primary breast cancer tissues (C).
Caspase-3 and actin were probed with corresponding specific antibodies using
Western blot.apoptosis appears not as significant as caspase-3. Please note
that MCF-7/C10 cells remain deficient in caspase-3 and
caspase-4. Whether caspase-10-mediated apoptosis in genistein
treated cells requires caspase-3 or caspase-4 will be addressed in
future studies.
4. Discussion
In this report, we focused on the correlation between
caspase-3 status and the differential responses to genistein in
Fig. 6. Genistein-induced apoptosis is not enhanced by caspase-10 over-
expression in MCF-7 cells. (A) Caspase-10 status in control (MCF-7/PV) and
caspase-10 reconstituted (MCF-7/C10) MCF-7 cells detected with Western blot.
(B) Genistein-mediated growth inhibition in control (MCF-7/PV) and MCF-7/
C10 cells. After genistein treatment at indicated concentrations for 6 days, the
survival fractions of the treated cells based on 8 parallel samples were
determined using MTTassay. (C) Genistein-induced apoptosis in control (MCF-
7/PV) and MCF-7/C10 cells. Cells from each line were inoculated into 24 well
plates at 1×105/well 24 h, followed by genistein treatment for 30 h. Apoptosis in
the treated cells was detected using an apoptosis ELSIA kit from Roche.
Fig. 5. Differential expression of more apoptotic factors between MFC-7 and
MDA-MB-231 cells. (A) mRNA levels of caspases-3, -5, -8, -9, and Apaf-1
(panel A1); and caspases 2, 4, 6, 7, and 10 (panel A2) in genistein treated MCF-7
and MDA-MB-231 cells. Total RNA was extracted from control (−) and
genistein (50 μM for 20 h) treated (+) cells. Three μg of total RNAwere used for
cDNA synthesis. One tenth of the RT product was used for amplification.
mRNA levels of the selected caspases were amplified by PCR for 30 cycles
using a multi-complex PCR kit (BioSource) containing specific primers of
corresponding caspases according to the manufacturer's protocol. P.C., positive
control from the kits. (B) Protein levels of caspases-4 and -10 in MCF-7 and
MDA-MB-231 cells detected with Western blot.
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that, other than ER-α status, the cellular factors that affect
genistein's sensitivity are largely unknown. Since genistein-
mediated non-estrogenic activities are also critical to its
inhibitory effect on tumor cell growth, identification of those
factors is important for the implication of genistein in clinical
oncology. We demonstrate that reconstitution of caspase-3 in
MCF-7 cells sensitizes those cells to genistein, and knock-
down caspase-3 from MDA-MB-231 cells renders the cells
resistant to genistein. These data indicate that the differential
responses between the two cell lines are not only determined
by ER status but also by caspase-3 status. Caspase-3
deficiency in MCF-7 cells contributes to its resistance to
genistein.
The mechanisms of genistein-mediated anti-tumor activ-
ities have been extensively studied [3]. Genistein treatment
elicits a number of cellular changes that modulate cell/tumor
growth and apoptosis. These include modulation of estrogenreceptor pathways, inhibition of protein tyrosine kinase and
topoisomerase I and II, induction of antioxidant activities,
inhibition of angiogenesis, downregulation of Bcl-2, and
upregulation of Bax [3]. In theory, any defect in the pathways
affected may contribute to genistein resistance. However, due
to functional overlap and interactions among these pathways,
the factors that have meaningful impact on genistein
sensitivities are elusive. As a phytoestrogen with SERM
properties, genistein's role in modulation of estrogen signal-
ing has been well established. The possible role of other
factors, such as caspase-3, is not adequately recognized.
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MDA-MB-231 cells, sensitive responses to genistein in
MDA-MB-231 cells, which express mutant p53, suggests
genistein-induced apoptosis may be p53 independent. How-
ever, functional regulation of p21/Waf-1, a p53 target gene,
appears to be required in genistein-mediated growth inhibi-
tion. Involvement of caspase-3 in genistein-induced apoptosis
has been reported by several groups [11,12,32] and mainly
indicated by cleavage of procaspase-3 and the use of synthetic
inhibitors, such as DEVD-CHO. Due to functional overlap
among effector caspases (caspases-3, -6 and -7), and since
DEVD-CHO may also affect caspases-6 and -7 [41], the
specific role of caspase-3 in genistein-induced apoptosis re-
mains undefined. With caspase-3 specific isogenic cell lines
(MCF-7/PV and MCF-7/C3), and caspase-3 shRNA-mediated
knockdown in MDA-MB-231 cells, our results provide direct
evidence supporting the critical role of caspase-3 in genistein-
induced apoptosis, and demonstrates a functional correlation
between caspase-3 status and the differential responses
between the two cell lines.
Caspase-3 is a key caspase that plays a critical role in
apoptotic machinery [29]. Activation of caspase-3 has been
employed as a marker of apoptosis induced by different
mechanisms [42]. Although the cells with deficient caspase-
3, such as MCF-7, can undergo apoptosis eventually, the
efficacy of the apoptotic responses in these cells is
significantly damaged [28,35]. Despite the fact that cas-
pase-3 is classified as an effector caspase, we have shown
that caspase-3 functions beyond a typical caspase. Besides its
role in the proteolysis of cellular death substrate, caspase-3
activity is required for maximal activation of caspases-6 and
-7 [35]. In particular, caspase-3 has feedback action on
apical caspases [43,44]. Collectively, the essential role of
caspase-3 in apoptotic execution may explain why caspase-3
status is critical to genistein-mediated apoptosis/growth
inhibition.
Soy/genistein has potential applications as a chemopreven-
tive or a pharmaceutical agent in anti-cancer studies [8]. The
chemopreventive effect of soy/genistein is usually associated
with intake of soy meal or low dose isoflavones. The serum
concentration of genistein under these conditions is generally
lower than 5 μM [45]. In contrast, test of genistein as a
pharmaceutical agent often uses concentrations up to 50 μM
[46]. In our study, we found that caspase-3 reconstitution
sensitized MCF-7 cells to genistein at both low and high
concentrations in MTT assay, which measured genistein's effect
after 6-day treatment. Since genistein induces both apoptosis
and cell cycle arrest, genistein-mediated apoptosis is usually
examined at higher concentrations for a shorter treatment.
Therefore, our observation may be more relevant to genistein's
therapeutic potential.
In this study we also examined caspase-3 expression in
nine breast cancer tissues and 18 breast cancer cell lines. The
common incidence of caspase-3 deficiency/downregulation in
breast cancer underscores the significance of the correlation
between caspase-3 status and genistein sensitivity. This is
further supported by previous reports showing the frequentdetection of caspase-3 downregulation in a larger cohort
setting [33]. Although the causes of caspase-3 deficiency/
downregulation are not clear, available reports suggest that
caspase-3 expression could be affected at multiple levels.
Caspase-3 defect in MCF-7 cells is caused by gene mutation
[28]. Caspase-3 transcription may be regulated by transcrip-
tion factor E2F-1 [47]. Based on reports on other caspases
[48], DNA methylation could also be a mechanism that
contributes to caspase-3 downregulation. These results
suggest that caspase-3 deficiency/downregulation is emerging
as a clinical problem. Since genistein is also being studied for
prevention/intervention of cancers originating from other
tissues such as prostate and pancreatic cancers [46,49],
identification of caspase-3 status as a determinant of genistein
sensitivity may have broader implications.
Results from multiplex PCR screening indicate that other
than caspase-3 status, MCF-7 cells also express lower levels of
caspases-10 and -4 than MDA-MB-231 cells. We also found
that genistein upregulates Apaf-1 and caspase-8 in MDA-MB-
231 cells but not in MCF-7 cells. Lower level expression of
caspase-10 in MCF-7 cells is consistent with a previous report
[27], whereas a lower level expression of caspase-4 in MCF-7
has not been documented. Genistein-induced differential
responses in Apaf-1 and caspase-8 appear to be a secondary
effector of other factors, such as modified E2F activities
[47,50].
With the MCF-7/C10 cell line established in our previous
study [27], we found that reconstitution of caspase-10 had
little effect on genistein-mediated overall growth inhibition
and apoptosis, as indicated by MTT and apoptosis ELISA
assays, respectively (Fig. 6). The results suggest that
functional impact of caspase deficiency may vary from one
caspase to another, which underscores the significance of
caspase-3 deficiency. Since MCF-7/C10 cells are also
deficient in caspases-3 and -4, the significance of caspase-
10 deficiency will be concluded after the tests in cells with
normal levels of other caspases. The specific impact of
caspase-4 deficiency, and -8 induction, on the differential
responses to genistein between the two cell lines will be
examined in future studies.
In summary, we examined the functional role of caspase-3
in genistein-induced apoptosis in MCF-7 and MDA-MB-231
cells. Using caspase-3 specific approaches, we demonstrated
that caspase-3 status is a critical determinant, in addition to
ER status, that contributes to the differential responses
between the two cell lines. The clinical relevance of this
finding is supported by the common incidences of caspase-3
downregulation in breast cancer tissues and cell lines.
Differential expression and responses of caspases-4, -8, -10
and Apaf-1 in genistein treated MCF-7 and MDA-MB-231
cells suggest that genistein sensitivity may be regulated by
more factors, which warrants further studies.
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